This Week In Diagnostics

IPSOGEN acquires rights for new cancer biomarkers IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN), has reported that it has acquired the worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes for diagnostic purposes from Baltimore,...

BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer

              Click below to hear live audio interview with Thomas Moore, CEO.   PRINCETON, N.J., Jan. 25  — Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary...

S.E.A. Medical Secures $3 Million in Series B Financing from JK&B Capital

SANTA CLARA, Calif.–S.E.A. Medical Systems Inc., a healthtech company focused on safety and management of IV medicine, today announced that it closed a $3 million Series B investment with Chicago-based venture capital firm JK&B Capital, which specializes in investments in Information Technologies,...

Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma

KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance from the U.S. Food and Drug Administration (“FDA”) to submit its Phase 3 protocol for...

This Week In Diagnostics

Clinical trial initiated for Trisomy 21 test Aria Diagnostics (formerly Tandem Diagnostics) says that it is initiating a multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal translucency ultrasound alone and in...

Miracor Aims to Cure More Than 350K Broken Hearts Per Year with New PCI Intervention System

Miracor Medical Systems is a privately held medical technology company based in Vienna, Austria and is aiming to help patients who have experienced cardiac surgery or suffer from acute coronary syndrome (ACS) improve their quality of life. Their main technology is called the PISCO® (Pressure-Controlled...